BioCardia, Inc.   Report issue

For profit Phase 1 Phase 3
Founded: San Carlos CA United States (1999)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2016
NCT02438306
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BioCardia, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

cardiamp (1 trial)

Drugs in Phase 1 Trials (2)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3